GlassScriptPhysician profile
Troy H Guthrie
NPI 1073500328
$1,258.30
in general payments reported to CMS, 2019-2025
39 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $73.70 · 2021: $289 · 2022: $217 · 2023: $204 · 2024: $29.73 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $205.92 | 2019-2025 | Reblozyl, Eliquis |
| Pfizer INC. | $128.59 | 2019-2023 | |
| Glaxosmithkline, LLC. | $112.68 | 2021 | |
| Amgen INC. | $106.61 | 2019-2023 | Lumakras |
| Bio Products Laboratory USA, INC. | $89.85 | 2022-2023 | Coagadex, Gammaplex |
| Janssen Biotech, INC. | $80.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $69.78 | 2019-2023 | |
| Apellis Pharmaceuticals, INC. | $54.54 | 2022 | |
| Merck Sharp & Dohme LLC | $38.79 | 2019-2023 | Keytruda |
| Seagen INC. | $36.05 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.32 | 2021-2022 | |
| Emd Serono, INC. | $32.09 | 2019 | |
| Exelixis INC. | $29.99 | 2022-2024 | Cabometyx |
| Astellas Pharma US INC | $25.56 | 2021 | |
| Eisai INC. | $24.49 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.41 | 2023 | Venclexta |
| Abbvie INC. | $22.33 | 2023 | |
| Servier Pharmaceuticals LLC | $20.33 | 2023 | |
| Rigel Pharmaceuticals, INC. | $19.40 | 2023 | Tavalisse, Rezlidhia |
| Astrazeneca Pharmaceuticals LP | $18.39 | 2021 | |
| Genzyme Corporation | $18.02 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $14.82 | 2019 | |
| Scpharmaceuticals INC. | $13.81 | 2024 | |
| Lilly USA, LLC | $13.32 | 2019 | |
| Daiichi Sankyo INC. | $12.51 | 2019 | |
| Verastem, INC. | $12.29 | 2019 |
13 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Guthrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.